SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information

On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG-IFN) therapy in chronic hepatitis B (CHB), but previously proposed prediction rules have shown limited external validity. We analyzed 803 HBeAg-positive patients treated with PEG-IFN in three global studies with available HBsAg measurements. A stopping-rule based on absence of a decline from baseline was compared to a prediction-rule that uses HBsAg levels of <1,500 IU/mL and >20,000 IU/mL to identify patients with high and low probabilities of response. Patients with an HBsAg level <1,500 IU/mL at week 12 achieved response (HBeAg loss with HBV DNA <2,000 IU/mL at 6 months posttreatment) in 45%. At week 12, patients without a decline in HBsAg achieved a response in 14%, compared to only 6% of patients with HBsAg >20,000 IU/mL, but performance varied across HBV genotype. In patients treated with PEG-IFN monotherapy (n = 465), response rates were low in patients with genotypes A or D if there was no decline of HBsAg by week 12 (negative predictive value [NPV]: 97%-100%), and in patients with genotypes B or C if HBsAg at week 12 was >20,000 IU/mL (NPV: 92%-98%). At week 24, nearly all patients with HBsAg >20,000 IU/mL failed to achieve a response, irrespective of HBV genotype (NPV for response and HBsAg loss 99% and 100%). Conclusion: HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB. HBV genotype-specific stopping-rules may be considered at week 12, but treatment discontinuation is indicated in all patients with HBsAg >20,000 IU/mL at week 24, irrespective of HBV genotype. (Hepatology 2013;53:872–880)

Abbreviations
ALT

alanine aminotransferase

AUC

area under the receiver-operating characteristic curve

cccDNA

covalently closed circular DNA

CHB

chronic hepatitis B

HBeAg

hepatitis B e antigen

HBsAg

hepatitis B surface antigen

HBV

hepatitis B virus

ULN

upper limit of normal.

Chronic hepatitis B (CHB) affects over 350 million people and is one of the leading causes of cirrhosis and hepatocellular carcinoma.[1] Antiviral treatment with peginterferon-alfa (PEG-IFN) may result in suppression of HBV DNA, hepatitis B e antigen (HBeAg) loss, and hepatitis B surface antigen (HBsAg) clearance.[2-5] Response to PEG-IFN therapy is durable, and patients with a sustained response have a reduced risk of developing hepatocellular carcinoma.[6-8]

However, clinical application of PEG-IFN is compromised by the limited response rates and the occurrence of side effects.[3-5] Careful selection of patients with the highest probabilities of response to PEG-IFN therapy is therefore essential. Several studies have shown that response rates are higher in patients with HBV genotypes A or B versus C or D,[3, 5, 9] and in patients with higher levels of alanine aminotransferase (ALT)[5, 9] and lower levels of HBV DNA.[9] Recent studies also suggest that host factors such as IL28B genotype, as well as viral characteristics such as absence of precore and/or core promoter mutants also influence response probabilities.[10, 11]

Nevertheless, prediction models incorporating these variables have only limited discriminatory capabilities. Recent studies have shown that serum levels of HBsAg correlate with intrahepatic cccDNA concentrations, and that achievement of a decline in HBsAg may herald induction of immune control.[12, 13] HBsAg levels during treatment with PEG-IFN can be used to identify patients with very high or very low probability of response,[5, 14] but interpretation of the findings is hampered by the use of different definitions of response across the studies. Furthermore, the external validity of proposed stopping-rules was shown to be limited,[15] which may be accounted for by the influence of HBV genotype on HBsAg levels and kinetics.[16] Since HBV genotype distribution differed considerably across the different study cohorts, only a combined analysis of individual patient data would allow for adequate assessment of the performance of the prediction rules across patients with different HBV genotypes.

The aim of the current study was therefore to evaluate the performance of two recently proposed prediction rules for HBeAg-positive CHB patients treated with PEG-IFN in a pooled dataset of patients participating in three of the largest randomized studies conducted worldwide.[3-5]

Patients and Methods

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information
Patients

In this study serum HBsAg levels were assessed in HBeAg-positive CHB patients who were previously enrolled in three separate pivotal multicenter randomized controlled trials on PEG-IFN therapy: the PEG-IFN alfa-2a Phase 3 study,[4] the HBV 99-01 study,[3, 14] and the Neptune study.[5] The PEG-IFN alfa-2a Phase 3 study compared PEG-IFN alfa-2a alone, lamivudine alone, or the two combined for a treatment duration of 48 weeks.[4] The HBV 99-01 study compared PEG-IFN alfa-2b alone with PEG-IFN alfa-2b combined with lamivudine for 52 weeks.[3] The Neptune study compared 48 weeks of PEG-IFN alfa-2a at the full dose of 180 μg/week for 48 weeks or 24 weeks, with a reduced dose of 90 μg/week for 48 or 24 weeks.[5] Only patients from the Neptune study randomized to the full dose for 48 weeks of PEG-IFN alfa-2a were eligible for participation in the current study. Response to treatment was assessed at 6 months posttreatment in all three studies, corresponding to study week 72 for the PEG-IFN alfa-2a Phase 3 and Neptune studies, and week 78 for the HBV 99-01 study. Inclusion criteria for these studies have been published previously but, in short: patients were positive for HBsAg for at least 6 months, positive for HBeAg, had an elevated ALT between 1 and 10 times the upper limit of normal (ULN), and HBV DNA levels exceeding 1.0 × 105 copies/mL. Exclusion criteria included coinfection with hepatitis C virus, hepatitis delta virus, or human immunodeficiency virus, decompensated liver disease, previous antiviral therapy within 6 months and preexisting neutropenia or thrombocytopenia.

Patients were eligible for the current analysis if they were infected with HBV genotypes A through D, had available HBsAg measurements at baseline, available HBsAg measurements at week 12 and/or week 24, and available data on treatment outcome at 6 months posttreatment. Out of a total of 899 patients with available data (PEG-IFN alfa-2a Phase 3: n = 542; HBV 99-01: n = 221; Neptune: n = 136), 803 patients complied with these criteria. Of the excluded 96 patients, 17 were infected with HBV genotypes other than A through D, 38 patients did not have available HBsAg levels at baseline and week 12 and/or 24, and 41 did not have available outcome data on (anti-)HBe, HBV DNA levels or HBsAg at 6 months posttreatment.

Laboratory Measurements

Serum HBsAg was quantified in samples taken at baseline, during the treatment period, and during follow-up. HBsAg was measured using the Architect (Abbott, Abbott Park, IL[17]) in patients from the PEG-IFN alfa-2a Phase 3 and the HBV 99-01 studies, and using the Elecsys HBsAg II (Roche Diagnostics, Indianapolis, IN) for patients enrolled in the Neptune study. A large previous study has shown a high correlation and close agreement between the two assays and demonstrated that prediction rules derived from measurements conducted with one platform may be confidently used on the other.[18] HBV DNA quantification was performed on Taqman-based polymerase chain reaction (PCR) assays with a lower limit of detection <400 copies/mL. ALT was measured locally in accordance with standard procedures and is presented as multiples of the ULN. HBV genotype was assessed using the INNO-LiPA line probe assay (Innogenetics, Ghent, Belgium).

Statistical Analysis

Response to treatment was defined as a composite endpoint of HBeAg loss with an HBV DNA level <2,000 IU/mL (∼10,000 copies/mL)[9] or HBsAg loss. The prediction rules evaluated in the current analysis included the stopping-rule proposed by Sonneveld et al.,[14] which recommended treatment discontinuation if there is no decline of serum HBsAg levels from baseline to weeks 12 or 24, and a prediction-rule identified previously by Piratvisuth et al.[19] on the PEG-IFN alfa-2a Phase 3 dataset, which used HBsAg levels of <1,500 IU/mL and >20,000 IU/mL at weeks 12 and 24 to identify patients with a high and low probability of response, respectively. The validity of these cutoffs was confirmed in the pooled dataset using logistic regression analysis fitting a spline with 5 knots. The optimal cutoff point was chosen based on a sensitivity of at least 95% and the highest negative predictive value (but always >90%) for response and HBsAg loss. SPSS v. 15.0 (Chicago, IL) and the SAS 9.2 program (SAS Institute, Cary, NC) were used to perform statistical analyses. All statistical tests were two-sided and were evaluated at the 0.05 level of significance.

Results

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information
Patient Characteristics

A total of 803 patients were analyzed, 104 (13%) treated with PEG-IFN alfa-2b alone, 100 (13%) treated with PEG-IFN alfa-2b with lamivudine (LAM), 361 (45%) treated with PEG-IFN alfa-2a alone, and 238 (30%) treated with PEG-IFN alfa-2a with LAM. Overall, 182 (23%) achieved a response (HBeAg loss with HBV DNA <2,000 IU/mL) and 39 (5%) cleared HBsAg by 6 months after PEG-IFN discontinuation. The baseline characteristics of patients with a response are compared to those without a response in Table 1. The baseline characteristics of patients treated with PEG-IFN alone were comparable to those who received PEG-IFN with LAM (Supporting Table 1).

Table 1. Characteristics of the Study Cohort
CharacteristicsResponse (n = 182)No Response (n = 621) 
  1. a

    Multiples of upper limit of the normal range.

Demography   
Mean (SD) age, years34 (11)32 (10)0.006
Male123 (68%)481 (78%)0.007
Race  0.330
Caucasian39 (21%)149 (24%) 
Asian138 (76%)442 (71%) 
Other5 (3%)30 (5%) 
PEG-IFN monotherapy109 (60%)356 (57%)0.538
Previous IFN26 (14%)67 (11%)0.195
Laboratory results   
Mean (SD) ALTa4.13 (3.1)3.79 (3.5)0.234
Mean (SD) HBV DNA, log c/mL9.11 (1.7)9.69 (1.8)<0.001
Mean (SD) HBsAg, log IU/mL3.97 (0.7)4.22 (0.7)<0.001
HBV Genotype  <0.001
A37 (20%)66 (11%) 
B55 (30%)149 (24%) 
C83 (46%)303 (49%) 
D7 (4%)103 (17%) 
HBsAg Decline According to Therapy Regimen and HBV Genotype

Baseline HBsAg levels significantly varied across HBV genotype, baseline levels were 4.59, 4.23, 3.91, and 4.53 log IU/mL for patients with genotypes A, B, C, and D (P < 0.001 by analysis of variance [ANOVA]). Mean HBsAg decline at 6 months posttherapy was 0.73 log IU/mL. HBsAg decline during treatment varied significantly by therapy regimen; patients treated with combination therapy (n = 338) achieved an end of treatment decline of 1.37 log IU/mL, compared to 0.92 in patients treated with PEG-IFN monotherapy (P < 0.001). However, HBsAg declines at 6 months posttreatment did not differ: declines were 0.68 and 0.80 log IU/mL for patients treated with PEG-IFN alone versus PEG-IFN with LAM (P = 0.293). HBsAg decline during treatment also varied across the HBV genotypes (Fig. 1). At 6 months posttreatment, mean declines were 1.60 and 0.96 log IU/mL for patients with genotypes A or B, versus 0.46 and 0.39 log IU/mL for patients infected with genotypes C or D (P < 0.001).

image

Figure 1. Change in serum HBsAg from baseline during treatment and 6 months of off-treatment follow-up across HBV genotypes A through D.

Download figure to PowerPoint

HBsAg Decline According to Response: Overall and by HBV Genotype

A decline of HBsAg levels was most pronounced in patients who achieved a response (Fig. 2A). HBsAg declines at end of treatment and at 6 months posttreatment were 2.39 and 1.98 log IU/mL in responders, compared to 0.73 and 0.34 log IU/mL in nonresponders (P < 0.001 for responders versus nonresponders). Similar patterns were observed across the HBV genotypes (Fig. 2B-E). Responders achieved more HBsAg decline by 6 months posttreatment than nonresponders, also when adjusting for combination therapy and HBV genotype: 2.05 versus 0.50 log IU/mL (P < 0.001).

image

Figure 2. Mean change in serum HBsAg from baseline in patients with a response (HBeAg loss with HBV DNA <2,000 IU/mL) in the overall cohort (A) and by HBV genotype A through D (B-E).

Download figure to PowerPoint

On-Treatment Prediction of Response Using HBsAg Levels at Weeks 12 and 24

Of the 803 enrolled patients, 779 (97%) had available HBsAg levels at week 12, and 788 (98%) had HBsAg levels at week 24. Analysis of the association between HBsAg levels and declines at weeks 12 and 24 and response to treatment showed that the previously identified cutoffs from the respective studies (<1,500 for identification of patients with a high likelihood of response, >20,000 IU/mL or absence of a decline for identification of nonresponders) were superior also in the pooled dataset (Supporting Fig. 1A-D).

At week 12, patients with HBsAg levels <1500 IU/mL had a probability of response of 45%, compared to 6% in patients with HBsAg >20,000 IU/mL (NPV: 94%, P < 0.001, Fig. 3A). The probability of HBsAg loss was 15% for patients with an HBsAg level <1,500 IU/mL at weeks 12 or 24. However, six patients with HBsAg >20,000 IU/mL at week 12 achieved HBsAg loss by 6 months posttreatment (6 out of 38 with HBsAg loss, or 16%). At week 24, only 4 of 162 patients with HBsAg >20,000 IU/mL achieved a response, and none cleared HBsAg (NPVs 98% and 100%, Fig. 3B).

image

Figure 3. Application of the prediction rules based on HBsAg levels at week 12 (A) and 24 (B) and HBsAg declines at weeks 12 (C) and 24 (D).

Download figure to PowerPoint

Of patients who did not achieve a decline in HBsAg levels from baseline to week 12, 14% achieved a response (NPV 86%, P = 0.001, Fig. 3C) and two cleared HBsAg (5% of all patients with HBsAg loss). Similar observations were made when decline was assessed at week 24 (Fig. 3D).

On-Treatment Prediction of Response at Weeks 12 or 24 Across HBV Genotypes

The performance of the prediction rules varied across HBV genotypes A through D (Tables 2, 3). At week 12, patients with HBV genotypes A, B, or C with HBsAg levels <1,500 IU/mL had a high probability of response (42%-86%), whereas such low HBsAg levels were hardly ever achieved in genotype D patients. Furthermore, application of the two stopping-rules (absence of a decline from baseline or an HBsAg level >20,000 IU/mL) yielded varying results across the HBV genotypes. In patients with genotype A, relatively high negative predictive values for response (83% and 88%) were achieved with both stopping-rules. However, 4 of 38 (10%) genotype A patients with an HBsAg >20,000 IU/mL would subsequently achieve HBsAg loss (20% of all genotype A patients with HBsAg loss), compared to none of the patients without an HBsAg decline at week 12 (NPVs for HBsAg loss 91% versus 100%). Discontinuation of PEG-IFN in genotype A patients with HBsAg >20,000 IU/mL at week 12 is therefore not always indicated.

Table 2. Observed Response Rates According to HBsAg Level at Week 12 Stratified by HBV Genotype
 Genotype A (n = 98)Genotype B (n = 199)
  1. Response was defined as HBeAg loss with HBV DNA <2,000 IU/mL.

Response<15001500-20,000>20,000<15001500-20,000>20,000
No2 (14%)25 (60%)35 (83%)35 (58%)75 (74%)35 (92%)
Yes12 (86%)17 (41%)7 (17%)25 (42%)26 (26%)3 (8%)
 Genotype C (n = 377)Genotype D (n = 105)
Response<15001500-20,000>20,000<15001500-20,000>20,000
No52 (58%)178 (81%)66 (99%)2 (100%)26 (93%)72 (96%)
Yes37 (42%)43 (20%)1 (2%)0 (0%)2 (7%)3 (4%)
Table 3. Observed Response Rates According to HbsAg Decline at Week 12 Stratified by HBV Genotype
 Genotype A (n = 98)Genotype B (n = 199)
  1. Response was defined as HBeAg loss with HBV DNA <2,000 IU/mL.

ResponseDeclineNo declineDeclineNo decline
No47 (58%)15 (88%)130 (73%)15 (68%)
Yes34 (42%)2 (12%)47 (27%)7 (32%)
 Genotype C (n = 377)Genotype D (n = 105)
ResponseDeclineNo declineDeclineNo decline
No203 (77%)93 (83%)49 (93%)51 (98%)
Yes62 (23%)19 (17%)4 (8%)1 (2%)

In patients with genotypes B and C, an HBsAg level >20,000 IU/mL at week 12 accurately identified patients with a low likelihood of response (Table 2), and for genotype C also HBsAg loss (NPV 100%). In patients with HBV genotype D, very few patients achieved a response, and absence of a decline at week 12 best identified nonresponders. The low number of genotype B and D patients with HBsAg loss (n = 4 and n = 2) precluded analysis of this endpoint in these patients.

At week 24, an HBsAg level of >20,000 IU/mL accurately identified patients with a low likelihood of response (Fig. 3B) across all genotypes (NPVs for genotype A, B, C, and D were 94%, 100%, 100%, and 97% for response, respectively, and 100% for HBsAg loss among HBV genotype A and C [the low number of genotype B and D patients with HBsAg loss precluded analysis of this endpoint among these patients]).

Performance of the Stopping-Rules in Patients Treated With PEG-IFN Monotherapy

Based on the varying performance of the stopping-rules across the HBV genotypes when applied at week 12, we compared the use of a stopping-rule based on an HBsAg level >20,000 IU/mL with a genotype-specific approach (application of no decline for genotypes A and D and >20,000 IU/mL for genotypes B and C). A grid-search of cutoff points showed that the genotype-specific approach at week 12 was superior to the use of an HBsAg >20,000 for all patients. At week 24, all patients with an HBsAg level >20,000 had a very low probability of response, irrespective of HBV genotype, and it was therefore applied to all patients. The proposed algorithm performed excellently when applied on the patients treated with PEG-IFN monotherapy (Table 4, Fig. 4). The NPVs for HBsAg loss were 100% at both week 12 and week 24 for patients with HBV genotypes A or C, but could not be analyzed for HBV genotypes B or D due to the low number of patients with HBsAg loss. Figure 4 shows the probability of response according to HBsAg level at week 24, stratified by HBV genotype.

Table 4. Performance of Proposed Stopping-Rules at Week 12 And 24 for Response (HBeAg Loss with HBV DNA <2,000 IU/mL) Across the HBV Genotypes in Patients Treated With Peginterferon Monotherapy for 1 Year
WeekHBV GenotypeApplied RuleN IdentifiedNPV Response
Week 12A (n = 55)No decline13 (24%)100%
 B (n = 120)>20,000 IU/mL24 (20%)92%
 C (n = 225)>20,000 IU/mL45 (20%)98%
 D (n = 54)No decline33 (61%)97%
Week 24A (n = 55)>20,000 IU/mL24 (44%)96%
B (n = 122)>20,000 IU/mL16 (13%)100%
C (n = 224)>20,000 IU/mL27 (12%)100%
D (n = 53)>20,000 IU/mL36 (68%)100%
image

Figure 4. Relationship between HBsAg level (in IU/mL) at week 24 of treatment and response (HBeAg loss with HBV DNA <2,000 IU/mL) 6 months off-treatment.

Download figure to PowerPoint

Performance in Patients With a High Pretreatment Likelihood of Response

A previous study analyzed the relationship between baseline factors and the probability of response to PEG-IFN in HBeAg-positive patients.[9] It was shown that patients with HBV genotype A with either high ALT (>2 times the ULN) or low HBV DNA (<9 log copies/mL) and patients with HBV genotype B or C with both high ALT and low HBV DNA levels had the highest pretreatment probability of response (>30%).[9] Patients with HBV genotype D generally had a low probability of response and were considered suboptimal candidates for PEG-IFN. In the current cohort, 195 patients complied with the criteria for high baseline probability of success (81 genotype A, 39 genotype B, 75 genotype C), and we observed a higher rate of response (34 versus 22%, P < 0.001) and HBsAg loss (10 versus 3%, P < 0.001) in these patients. At week 24, only 2 of 26 patients with an HBsAg level >20,000 IU/mL achieved a response (NPV 92%) and none cleared HBsAg (NPV 100%). A lower NPV for response was observed at week 12 (81%), suggesting that decision-making is best postponed in this subset.

Discussion

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information

This study shows that quantification of HBsAg in HBeAg-positive patients receiving PEG-IFN may help individualize on-treatment decision-making. At week 24, all patients with HBsAg levels >20,000 IU/mL have a low probability of response, irrespective of HBV genotype, and PEG-IFN discontinuation is indicated. Use of HBV genotype specific stopping-rules may also be considered at week 12.

PEG-IFN is a powerful treatment option for HBeAg-positive CHB, but the limited response rates achieved in the general patient population, as well as the frequent side effects, prohibit widespread use.[20] Previous studies have used serum levels of HBV DNA and HBeAg during PEG-IFN therapy to identify patients with a low probability of response.[21-23] HBeAg levels yielded higher negative predictive values than did HBV DNA levels, but both could only be confidently used after at least 24 weeks of therapy.[24] Unfortunately, HBeAg levels in serum are also influenced by the presence of precore and core promoter mutants, which may impair the reliability of prediction.[10] Recent studies have therefore focused on the use of serum HBsAg levels for monitoring of PEG-IFN efficacy. The current study, a pooled analysis of 803 patients from three of the largest global cohorts and treated with both formulations of PEG-IFN alfa, shows that HBsAg decline during PEG-IFN therapy is strongly associated with the occurrence of a response to treatment. Importantly, the pronounced HBsAg decline observed in responders was apparent across all major HBV genotypes. Given the association of HBsAg kinetics with response, several of us have attempted to use HBsAg levels at weeks 12 and 24 of treatment to estimate the probability of response. Sonneveld et al. showed that in a cohort of predominantly Caucasian patients, absence of a HBsAg decline from baseline at week 12 identified patients with a low likelihood of response. Conversely, Piratvisuth et al.[19] found that only few patients with HBsAg >20,000 IU/mL at the same timepoint achieved a response. Subsequent studies have shown the suboptimal external validity of these prediction rules.[15, 16] Interpretation was further hampered by the use of different definitions of response; HBeAg loss with HBV DNA <10,000 copies/mL in one study and HBeAg seroconversion in others.[14, 19]

The current study finally resolves these issues by providing a pooled analysis of the patients enrolled in the previous studies, allowing for careful stratified analysis across HBV genotypes and using a clinically relevant definition of response. We defined response as HBeAg loss with HBV DNA <2,000 IU/mL, since this endpoint is highly durable[7, 16] and since patients with low HBV DNA levels are less likely to develop HBV-related liver complications or require antiviral therapy.[25-29] Our results indicate that, when assessed at week 12, both an HBsAg level >20,000 IU/mL as well as the absence of a decline from baseline may identify nonresponders to PEG-IFN, but the differences in performance across HBV genotypes warrant careful application. The requirement for different HBsAg cutoffs across HBV genotypes at week 12 of treatment may partly reflect the differences in baseline HBsAg levels; patients with HBV genotypes A had substantially higher levels than those with genotype B or C, which may account for the observation that patients with genotypes A with HBsAg levels >20,000 IU/mL at week 12 may still achieve a response and HBsAg loss. Furthermore, a recent study in a cohort of mostly patients with genotypes A and D showed that HBeAg-positive patients with only detectable wildtype virus (i.e., no detectable precore and/or core promoter mutants) have both higher baseline levels of HBsAg and a higher probability of HBsAg loss after PEG-IFN therapy.[10] The high rate of response and HBsAg loss observed in genotype A patients with HBsAg >20,000 IU/mL at week 12 (17% and 10%, respectively) is an important finding, and shows that HBV genotyping is essential if a week 12 prediction-rule is to be used in areas where HBV genotype A is prevalent. Importantly, baseline probabilities of response may also influence the performance of the proposed stopping-rules, and decision-making at week 12 is more difficult in patients with a high baseline probability of response. For these patients, decision-making is best postponed until week 24.

Fortunately, an HBsAg level >20,000 IU/mL at week 24 may be confidently used as a stopping-rule for all patients with high NPVs for response and HBsAg loss, irrespective of HBV genotype. Given the wide availability of HBsAg quantification platforms, the low cost of the test, and the excellent predictive performance observed in the current study, assessment of the HBsAg concentration at week 24 should be considered a vital part of optimal PEG-IFN therapy.

Side effects and patient preferences should also be taken into consideration, and the performance of the prediction algorithm should be reevaluated when data become available on extension of PEG-IFN therapy beyond 48 weeks or when a combination with nucleo(s)tide analogs other than LAM is used. Nevertheless, HBsAg-based response-guided therapy is a valuable tool for optimization of PEG-IFN therapy, and can help with achieving higher response rates for every therapy course completed. Early identification of nonresponders may help make this treatment modality more acceptable to patients, physicians, and healthcare policy makers and possibly increase the cost-effectiveness of PEG-IFN in HBeAg-positive CHB.

Limitations of the current study are that a subset of patients was treated with a combination of PEG-IFN + LAM. We have therefore performed separate analyses in patients treated with PEG-IFN alone, as shown in Table 4. We enrolled a majority of patients with HBV genotypes B and C compared with A and D, and further confirmation of our findings may therefore be required in the latter groups. Since only a limited group of patients achieved HBsAg loss, further studies may be required to confirm the high NPVs observed for this endpoint, particularly for patients with HBV genotypes B and D. Previous studies have shown that patients with HBV genotype D respond poorly to PEG-IFN therapy[9] and PEG-IFN may not be an optimal choice for some of these patients given the low rate of response we observed in the current cohort.

In conclusion, the current study shows that HBsAg levels can be confidently used to guide therapy decisions in HBeAg-positive patients treated with PEG-IFN. Discontinuation of PEG-IFN treatment is indicated in all patients with HBsAg levels >20,000 IU/mL after 24 weeks of PEG-IFN therapy.

Author Contributions

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information

Study coordination and design, data collection, data analysis, writing of article, approval of final version: M.S., H.L.Y.C., B.E.H., H.L.A.J. Data collection, critical review of the article, approval of final version: T.P., J.D.J., S.Z., E.G., Y.F.L., Q.X., E.J.H. Statistical analysis, critical review of the article, approval of final version: B.E.H. The authors had complete access to all data, and take responsibility for its integrity and the accuracy of the analysis.

References

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information
  • 1
    Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153-161.
  • 2
    Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
  • 3
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
  • 4
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
  • 5
    Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-1599.
  • 6
    van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-810.
  • 7
    Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
  • 8
    Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.
  • 9
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
  • 10
    Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B. Hepatology 2012;56:67-75.
  • 11
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513-520.
  • 12
    Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 — a core group report. J Hepatol 2011;55:1121-1131.
  • 13
    Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012;61:641-645.
  • 14
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline. Hepatology 2010;52:1251-1257.
  • 15
    Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 2010;53:1054-1055.
  • 16
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-á2b: relation to response and HBV genotype. Antivir Ther 2012;17:9-17.
  • 17
    Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-222.
  • 18
    Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51:175-178.
  • 19
    Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011 [Epub ahead of print].
  • 20
    Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010;9:91-98.
  • 21
    ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, et al. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther 2007;12:1285-1294.
  • 22
    ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006;44:721-727.
  • 23
    Hansen B, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-1142.
  • 24
    Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.
  • 25
    Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57:84-90.
  • 26
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
  • 27
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
  • 28
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
  • 29
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.

Supporting Information

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Author Contributions
  7. References
  8. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
hep26436-sup-0001-suppfig1A.tif86KSupporting Figure 1A Relationship between HBsAg levels and declines at week 12 (A and B) and at week 24 (C and D) and response to peginterferon therapy.
hep26436-sup-0002-suppfig1B.tif76KSupporting Figure 1B Relationship between HBsAg levels and declines at week 12 (A and B) and at week 24 (C and D) and response to peginterferon therapy.
hep26436-sup-0003-suppfig1C.tif88KSupporting Figure 1C Relationship between HBsAg levels and declines at week 12 (A and B) and at week 24 (C and D) and response to peginterferon therapy.
hep26436-sup-0004-suppfig1D.tif74KSupporting Figure 1D Relationship between HBsAg levels and declines at week 12 (A and B) and at week 24 (C and D) and response to peginterferon therapy.
hep26436-sup-0005-supptab1.doc27KSupporting Table 1: Characteristics of the study cohort by assigned therapy regimen

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.